Introduction: Bioanalytical Method Transfer Between CROs is one of the most operationally demanding activities in clinical drug development, particularly during […]
Introduction The FDA’s Product-Specific Guidance for Tirzepatide outlines the regulatory, analytical, formulation, and drug-device combination product requirements that generic manufacturers
FDA Product-Specific Guidance for Tirzepatide: A Complete ANDA Development Roadmap Read More »
Introduction: PLGA vs PLGA-PEG for nanoparticle drug delivery is one of the first formulation decisions a sponsor faces when designing
What Is the Difference Between PLGA and PLGA-PEG for Nanoparticle Drug Delivery? Read More »
Introduction A specialized Biosimilar Functional Bioassay Development Service provides Mechanism of Action (MoA)-reflective cell-based and binding assays that are specifically
Introduction The optimization of Purification Techniques for Peptide-Oligonucleotide Conjugates depends on the strategic application of orthogonal chromatographic methodologies capable of
Purification Techniques for Peptide-Oligonucleotide Conjugates (HPLC, Ion Exchange, SEC) Read More »
Introduction The decision to adopt a consolidated or split Drug Substance vs Drug Product CDMO model plays a pivotal role
Drug Substance vs Drug Product CDMO: Understanding the Split and When to Use Each Read More »
Introduction A comprehensive analytical data package prepared for an Investigational New Drug (IND) submission provides regulatory agencies with robust structural,
Introduction Peptide-oligonucleotide conjugates gain entry into cells mainly through energy-dependent endocytosis or energy-independent direct plasma membrane translocation, with the dominant
Introduction Obtaining approval for an Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) requires manufacturers
